戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 conversion of UDP-GlcNAc into UDP-N-acetyl-D-mannosamine.
2           The (alpha1-->6)-linked N-acetyl-D-mannosamine-1-phosphate meningococcal capsule of serogro
3 which in Nm serogroup A consists of N-acetyl-mannosamine-1-phosphate units linked together by phospho
4 zene in the presence of Rh2(OAc)4, providing mannosamine 2-N,3-O-oxazolidinones.
5  (Glc6P), and a nonnatural activating sugar, mannosamine 6-phosphate (MaN6P), reveal a binding mode s
6 charide standard plots for respective sugars mannosamine-6-phosphate, sialic acid, galactose- and glu
7 g membranes prepared from cells treated with mannosamine, a GPI biosynthesis inhibitor.
8 , without affecting the incorporation of [3H]mannosamine, a precursor of sialic acid residues.
9                Peracetylated N-azidoacetyl-d-mannosamine (Ac4ManNAz) conjugated with neuroactive carr
10                                              Mannosamine, an inhibitor of GPI biosynthesis, inhibits
11                         In previous studies, mannosamine analogues bearing simple N-acyl groups up to
12 ls were grown in the presence of synthetic d-mannosamine analogues that can modify the conformation o
13                             PFAA-derivatized mannosamine and galactosamine were successfully transfor
14 onversion of a panel of azide-functionalized mannosamine and glucosamine derivatives into cell-surfac
15 synthesis through condensation of N-acetyl-D-mannosamine and phosphoenolpyruvate.
16  by metabolic conversion of synthetic N-acyl mannosamines and are typically incorporated into cell-su
17 cells were incubated with different N-acyl-d-mannosamines, and modified forms of GM3 expressed on tum
18 ve activities toward d-allose and N-acetyl-d-mannosamine are largely unaffected by the glucokinase-en
19                  Per-butanoylated N-acetyl-D-mannosamine (Bu(4)ManNAc), a SCFA-hexosamine cancer drug
20  by exogenously added N-acetylmannosamine or mannosamine but not by the same concentrations of N-acet
21                     Recently, we showed that mannosamine can prevent the growth of P. falciparum by i
22 es that utilize acetyl-CoA to decorate the D-mannosamine capsule of N. meningitidis serogroup A.
23 mine 2-epimerase (wecB) and a UDP-N-acetyl-d-mannosamine dehydrogenase (wecC) were identified in the
24 nthesized by the parasite in the presence of mannosamine demonstrates that the effect is because of t
25 ere was a significant azido-labeled N-acetyl-mannosamine-dependent increase in tumor-to-tissue contra
26 osyl donors for the elaboration of various 2-mannosamine frameworks.
27 ailable amino sugars, including glucosamine, mannosamine, galactosamine, and muramic acid, as laborat
28 a, or uridine but not by control metabolites mannosamine, galactose, mannose, succinate, or pyruvate.
29 h any other sugar, including: galactosamine, mannosamine, Glc, GlcNAc, GalNAc, mannose, 2-deoxyglucos
30                                              Mannosamine has no effect on the development of either r
31   Starting from the commercially available D-mannosamine hydrochloride (5), gram quantities of both 1
32  two readily available starting materials, D-mannosamine hydrochloride and the microbial oxidation pr
33 ne sulfate, galactosamine hydrochloride, and mannosamine hydrochloride-were examined for the linearit
34                            In other systems, mannosamine inhibits GPI biosynthesis by interfering wit
35                      The data also show that mannosamine inhibits GPI biosynthesis by interfering wit
36         Peracetylated azido-labeled N-acetyl-mannosamine, injected intraperitoneally, was used as the
37                  The d-allose and N-acetyl-d-mannosamine kinases of Escherichia coli K-12 are diverge
38 ody fluids showed an elevation in N-acetyl-D-mannosamine levels, and patient-derived fibroblasts had
39 gulatory functions, was examined utilizing D-mannosamine (ManN) as a tool to identify mannosyltransfe
40 eport the identification of the hexosamine D-mannosamine (ManN) as an EC mitogen and survival factor
41                               The N-acetyl-D-mannosamine (ManNAc) analog Ac5ManNTGc, a non-natural me
42  an aldolase that cleaves NANA into N-acetyl mannosamine (manNAc) and pyruvate.
43 thway in mammalian cells utilizes N-acetyl-D-mannosamine (ManNAc) as a natural metabolic precursor an
44  we fed the sialic acid precursor N-acetyl-D-mannosamine (ManNAc) to NPHS2-Angptl4 transgenic rats it
45  of glucose (Glc), galactose (Gal), N-acetyl mannosamine (ManNAc), and N-acetylglucosamine (GlcNAc).
46 c acid (Neu5Ac) from pyruvate and N-acetyl-D-mannosamine (ManNAc).
47 istered the sialic acid precursor N-acetyl-D-mannosamine (ManNAc).
48 riers were then conjugated with N-butanoyl-d-mannosamine (ManNBut) with a goal to achieve modulation
49 reference for the same geometry that put the mannosamine moiety of one substituent close to the thiou
50 ays, precursors based on sialic acid and not mannosamine must be used.
51 lth like the structural analogues N-acetyl-D-mannosamine (NADM) and N-acetyl-D-glucosamine (NADG).
52 he anomeric n-pentenyl glycosides of N-Cbz 2-mannosamine oxazolidinones were converted separately to
53                               Treatment with mannosamine precursors of sialic acid (to alter NeuAc/Ne
54 on with the sialic acid precursor N-acetyl-D-mannosamine restored IgG sialylation and preserved insul
55 italicus TagA enzyme bound to UDP-N-acetyl-d-mannosamine, revealing the molecular basis of substrate
56 onjugated with triacetylated N-azidoacetyl-d-mannosamine (RR-S-Ac3 ManNAz) was developed to enable tu
57 atalysis by encapsulating the UDP-N-acetyl-d-mannosamine substrate, presenting three highly conserved
58 s (CTLs) were incubated with N-azidoacetyl-D-mannosamine-tetraacylated (Ac(4)ManNAz) for incorporatin
59 ells an unnatural monosaccharide, a modified mannosamine that replaced the acetyl group with a levuli
60 ugate vaccine with systemic N-phenylacetyl-d-mannosamine treatment is a promising immunotherapy for f
61                                              Mannosamine treatment, which down-regulates cell-surface
62                             N-Phenylacetyl-d-mannosamine was efficiently incorporated in a time- and
63 utanoyl, and N-phenylacetyl derivatives of d-mannosamine were synthesized, and their efficiency as bi
64 saccharides, glucosamine, galactosamine, and mannosamine, were derivatized with [Co(DAP)2Cl2]Cl, and
65  with K1 >3000 m(-1) for axially substituted mannosamine, whereas a positively charged version binds
66          An unnatural derivative of N-acetyl-mannosamine, which has a ketone group, was converted to